Wif1 overexpression accelerated osteogenic differentiation by activating genes related to late-stage osteogenic differentiation and mitophagy processes. Moreover administering Wif1-overexpressing ...
NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Schematic diagram illustrating how transplanted young mitochondria activate the AKAP1/cAMP/PKA pathway in aged PDLSCs, restoring mitochondrial membrane potential (ΔΨm), reducing ROS, and enhancing ...
New research uncovers how the Clec14a protein in capillary endothelial cells controls bone growth and maturation, revealing a key mechanism in skeletal development. Study: Type-H endothelial cell ...
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and ...
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback